BPB Reports

Paper Details

BPB Reports
Vol. 3 No. 1 p.39-44 2020
Regular Article
Persistence, Effects, and Adverse Events Associated with Real-World Daily Teriparatide Use in Japanese Patients with Osteoporosis
  • Tomoko Matsumoto (Graduate School of Pharmaceutical Sciences, Osaka University / trinity.seri@gmail.com)
Tomoko Matsumoto 1) , Kazuyuki Niki 1) , Asuka Hatabu 1) , Takuya Oshima 2) , Kimihiko Sato 2) , Mikiko Ueda 1) , Tetsuya Sato 2) , Etsuko Uejima 1)
1) Graduate School of Pharmaceutical Sciences, Osaka University , 2) Sato Orthopedic Clinic
Received: November 06, 2019;   Accepted: January 06, 2020;   Released: February 14, 2020
Keywords: osteoporosis, old-old, first injection, fracture, adverse event

Few studies have addressed the effects and adverse events associated with daily teriparatide use, as well as the adherence and causes for non-adherence, among Japanese patients with osteoporosis, particularly those older than 80 years. In this study, we aimed to clarify various parameters associated with daily teriparatide use in Japanese patients with osteoporosis in a real-world clinical setting. This retrospective study compared the persistence of daily teriparatide use and the associated effects and adverse events in older (≥80 years, n=52) and younger patients (<80 years, n=106) treated with teriparatide between May 2013 and May 2018 at a single orthopedic clinic. We observed a significantly higher treatment completion rate among younger patients compared to their older counterparts (59.6% vs. 40.6%, p=0.036). Of the 74 patients (both patient groups) who completed a 24-month treatment course, only one (1.35%) developed new vertebral fractures. Our findings suggest that older patients would benefit from consistent osteoporosis treatment, particularly with a generally safe and effective agent, such as teriparatide. However, Log-rank test also shows the older patients exhibits a greater tendency to drop out than the younger patients (p=0.0238). The older patients tended to continue to drop out from the beginning. Accordingly, our results emphasize the importance of interventions, especially continuous encouraging from the first self-injection of teriparatide.